Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients

Table 1

Baseline patient characteristics.

	Axial SpA with less than two-year disease duration ()
Age (years)	21.00 ± 7.05
Sex
Male	58 (82.9%)
Female	12 (17.1%)
Family history of AS	13 (18.6%)
HLA-B27(+)	63 (90.0%)
Peripheral symptoms (arthritis or enthesitis)	17 (24.3%)
Disease duration (years)	1.41 ± 0.57
BASDAI (0–100 mm VAS)	46.86 ± 10.48
BASFI (0–100 mm VAS)	23.41 ± 19.46
BAS-G (0–100 mm VAS)	49.95 ± 19.16
ASDAS	3.02 ± 1.25
MRI score
Sacroiliac joint	20.40 ± 10.44
Lower spine (T10-S2)	1.86 ± 3.85
Modified Schober test (cm)	4.63 ± 1.69
CRP (mg/L)	31.43 ± 38.33
ESR (mm/hr)	34.75 ± 30.48

Data reported are mean (standard deviation) or number (%) of patients.
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index, BAS-G: Bath Ankylosing Spondylitis Global assessment, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, HLA: human leukocyte antigen, MRI: magnetic resonance imaging, and VAS: visual analog scale.